Details for New Drug Application (NDA): 087439
NDA 087439 describes WELLCOVORIN, which is a drug marketed by Glaxosmithkline and is included in five NDAs. Additional details are available on the WELLCOVORIN profile page.
The generic ingredient in WELLCOVORIN is leucovorin calcium. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leucovorin calcium profile page.
The generic ingredient in WELLCOVORIN is leucovorin calcium. There is one drug master file entry for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the leucovorin calcium profile page.
Summary for 087439
| Tradename: | WELLCOVORIN |
| Applicant: | Glaxosmithkline |
| Ingredient: | leucovorin calcium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 087439
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | Strength | EQ 5MG BASE/ML (EQ 5MG BASE/ML) | ||||
| Approval Date: | Oct 19, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;INTRAMUSCULAR, INTRAVENOUS | Strength | EQ 25MG BASE/5ML (EQ 5MG BASE/ML) | ||||
| Approval Date: | Oct 19, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
